PRESS-RELEASE ·Filed May 12, 2026

ATAI

AtaiBeckley Inc.
MIXED
Impact 5/10
Horizondays Processed4mo ago WireGlobeNewswire
Press release: earnings
Actionable Insight ◆ Mixed

The earnings beat may drive short-term momentum, but focus on upcoming Phase 3 initiation for BPL-003 (Q2 2026) and VLS-01 Phase 2 data (Q4 2026) as key catalysts. Monitor cash burn rate and revenue trajectory for sustainability.

DirectionMixed
Confidencehigh
Horizondays
Final — all horizons settled through T+60d ⚠ clustered
ATAI ▲ +73.01% at T+60d
NEUTRAL call ✓ call won +73.01% · α vs SPY +68.63% · entry $4.15 → $7.18
Entry anchored
May 11, 03:59 PM ET
via exchange tick
T+1d
+2.17%
call +2.17% · α +1.59%
$4.24
settled 5mo ago
T+5d
0.00%
call 0.00% · α -0.08%
$4.15
settled 5mo ago
T+20d
-8.92%
call -8.92% · α -7.19%
$3.78
settled 4mo ago
T+60d
+73.01%
call +73.01% · α +68.63%
$7.18
settled 8w ago

Price Chart

Loading chart...

Executive Summary

AtaiBeckley reported Q1 2026 EPS of -$0.08, beating consensus of -$0.11 by 27%, and revenue of $954K, well above the $91K estimate. However, revenue declined 39% YoY and net loss widened to $29.8M, while R&D spending increased 54% to support pipeline advancement. The beat provides near-term support, but YoY degradation and heavy cash burn suggest caution.

Key Financial Metrics

EPS
$-0.08
est $-0.11 · +27.3%
Revenue
$954.0K
est $91.0K · +948.4% · -38.6% YoY
Rating
beat

Key Facts

  • EPS -$0.08 beat consensus -$0.11 (27% beat)
  • Revenue $954K vs consensus $91K (but down 39% YoY from $1.55M)
  • Net loss widened to $29.8M from $26.4M YoY
  • R&D expenses rose 54% to $17.4M; G&A up 36% to $14.4M
  • Cash $209.9M, expected to fund operations into 2029

Financial Impact

EPS beat of $0.03 vs consensus and revenue beat of ~$863K, partially offset by YoY decline in revenue and increased losses.

epsrevenuenet_losscash_position

Risk Factors

  • Clinical trial failure or delays for BPL-003, VLS-01, or EMP-01
  • Continued cash burn with no near-term revenue growth
  • Share dilution risk given pre-funded warrants and negative EPS trajectory

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
95% bullish (20 analysts)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3292770
17 reports for ATAI
Performance horizon
100% Hit rate 6 of 6 directional calls best @ T+60▲ +38.03%Apr 8, 2026
Filters
Rows
Reports for ATAI — sortable, filterable
TypeNow
Sep 11, 2026
21d ago
25-NSE
BEARISH ★ 9/10
$7.30 awaiting T+20awaiting T+20——
Aug 10, 2026
7w ago
DEFM14A
BULLISH ★ 7/10
$7.25 $7.28▲ +0.41%▲ +1.33%—
Aug 9, 2026
7w ago
Institutional Cluster
BULLISH ★ 6/10
$7.25 $7.28▲ +0.41%▲ +1.33%—
Jul 16, 2026
11w ago
DEFA14A / 8-K
BULLISH ★ 7/10
$7.15 $7.25▲ +1.40%▼ −2.22%—
Jul 7, 2026
12w ago
144
NEUTRAL ★ 3/10
$5.17 $7.22▲ +39.65%▲ +36.38%—
Jul 6, 2026
12w ago
Press Release
NEUTRAL ★ 4/10
$4.96 $7.18▲ +44.76%▲ +45.32%—
Jun 26, 2026
14w ago
144
NEUTRAL ★ 3/10
$5.36 $7.18▲ +33.96%▲ +34.23%—
Jun 25, 2026
14w ago
144
NEUTRAL ★ 3/10
$5.29 $7.17▲ +35.54%▲ +34.28%—
Jun 3, 2026
17w ago
8-K
NEUTRAL ★ 2/10
$4.53 $5.19▲ +14.57%▲ +15.57%—
May 12, 2026
20w ago
Press Release
MIXED ★ 5/10
$4.15 $3.78▼ −8.92%▼ −7.19%—
Showing 10 of 17

US Market Status

Market Closed — Opens Mon (37h 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published May 12, 2026